Industry Partnerships

The Children’s Oncology Group (COG) has a long and successful history of strategic collaboration with Industry Partners, from emerging biotech innovators to global pharmaceutical leaders. Through flexible partnership models, COG aligns scientific expertise, operational excellence, and regulatory rigor to support a wide range of industry objectives.

Partnering with COG provides access to a world-class pediatric cancer research infrastructure spanning more than 220 sites and a global network of experienced investigators, enabling broad patient access, efficient trial accrual, and meaningful data generation. COG’s scale and capabilities support the generation of robust clinical, real-world, and patient experience data that help advance new pediatric cancer treatments from research through regulatory pathways.

Since its inception, COG has conducted hundreds of clinical trials across pediatric, adolescent, and young adult cancers. COG trial data has supported numerous regulatory pediatric oncology indication approvals, advancing standards of care.

Why Partner with COG

COG offers Industry Partners unmatched scale as the world’s largest pediatric cancer research consortium, with a network of more than 13,500 experts across more than 220 institutions. More than 80% of children and adolescents with cancer in the United States are treated at a COG-affiliated institution, providing partners access to the patient populations necessary to efficiently enroll robust clinical trials.

COG’s extensive research infrastructure includes Project:EveryChild, a landmark initiative that has helped build a biorepository of more than 400,000 annotated biospecimens representing over 300 pediatric cancer diagnoses, creating powerful opportunities for translational, biomarker, and precision medicine research. With decades of experience conducting practice-changing clinical trials, COG has generated data that has supported numerous FDA approvals, label expansions, and advancements in pediatric oncology standards of care.

Advancing New Therapies

COG is the world’s most experienced pediatric oncology consortium for the clinical development of new cancer therapeutics for children, adolescents, and young adults. Through a dedicated early-phase network of specialized institutions, COG provides the infrastructure, scientific leadership, and operational expertise necessary to conduct phase 1 and phase 2 trials, including pharmacokinetic studies.

COG’s unmatched scale and access to broad patient populations enable the successful enrolment of eligible participants across even the rarest cancers, helping advance promising therapies through critical stages of development.

For later-stage studies, COG offers the strategic planning, scientific prioritization, and global research infrastructure required to design and execute complex phase 3 trials capable of changing standards of care. Across every stage of development, COG provides a proven framework for advancing promising pediatric cancer therapies.

FDA and EMA Experience

The regulatory landscape for childhood cancer drug development is evolving, making pediatric oncology an increasing priority for pharmaceutical and biotech companies. COG guides industry partners in shaping pediatric drug development strategies, including development plans that support pediatric exclusivity and the creation of feasible Pediatric Investigation Plans (PIPs).

COG’s decades of pediatric oncology leadership provide industry partners with expert scientific and clinical insight that can strengthen early proposals and refine them into feasible studies designed to generate meaningful pediatric data. By combining deep knowledge of current treatment landscapes with practical trial design expertise, COG helps partners build development plans positioned for clinical and regulatory success.

Learn More

To learn more, contact the COG Industry Sponsored Trials Program (IST) at ISTProgram@childrensoncologygroup.org or (626) 241-1512.